GALDERMA GRP AG
164,10€
-0,65 (-0,39%)
17.09.2026, 22:57:45 Uhr
WKN: A407X6 ISIN: CH1335392721 Wertpapiertyp: Aktie Währung: Euro
- 1T
- 1W
- 1M
- 3M
- 6M
- 1J
- 3J
- 5J
- 10J
- Max
Zuletzt angesehen
- SMI ® +78,65 +0,57% 13.947,31
Kursperformance
| Zeitraum | Kurs | % |
|---|---|---|
| 1 Tag | 164,10€ | -0,39% |
| 1 Woche | 174,16€ | -5,40% |
| 1 Monat | 186,96€ | -11,88% |
| 6 Monate | 160,00€ | +2,97% |
| Lfd. Jahr (YTD) | 176,25€ | -6,53% |
| 1 Jahr | 158,84€ | +3,72% |
| 3 Jahre | -- | -- |
| 5 Jahre | -- | -- |
Kursdaten
| Kurs | 164,10€ |
| Eröffnung | 164,10€ |
| Geld | 165,80€ |
| Brief | 167,05€ |
| Tages-Hoch | 164,10€ |
| Tages-Tief | 164,10€ |
| 52 Wochen-Hoch | 200,90€ |
| 52 Wochen-Tief | 141,50€ |
| Allzeit-Hoch | 200,90€ |
| Allzeit-Tief | 111,00€ |
Nachrichten
- BUSINESS WIRE: Galderma’s Restylane® Volyme™ Demonstrates High Effectiveness, Satisfaction and a Robust Safety Profile in Chinese Patients With Temple Hollowing - 16.09.2026, 07:00:01 Uhr
- BUSINESS WIRE: Galderma Receives European Union Approval for Restylane® Shaype™: the First-and-Only Bone-Mimicking Hyaluronic Acid Injectable for Facial Shaping - 11.08.2026, 07:00:02 Uhr
- BUSINESS WIRE: Galderma Reports Record First Half 2026 Net Sales of 3.134 Billion USD and 24.6% Year-on-Year Growth at Constant Currency, Raises Net Sales Guidance for the Full Year - 23.07.2026, 07:00:02 Uhr
- BUSINESS WIRE: Galderma Launches Alastin® in Japan and Key Markets Across Asia Pacific, Expanding Its Footprint in the Region - 20.07.2026, 07:00:03 Uhr
- BUSINESS WIRE: Landmark Global Galderma Survey Shows 9 out of 10 People Are Affected by Skin Quality Concerns - 07.07.2026, 07:00:06 Uhr
- BUSINESS WIRE: Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States - 01.07.2026, 07:00:07 Uhr
- BUSINESS WIRE: Galderma Unveils New Global Survey Data Exploring the Evolving Expectations and Experiences of Patients and Healthcare Professionals With Anti-wrinkle Treatments - 11.06.2026, 07:00:03 Uhr
- BUSINESS WIRE: Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch - 22.05.2026, 18:25:04 Uhr
- BUSINESS WIRE: Galderma Reports Strong Start to the Year, Delivering First Quarter 2026 Net Sales of 1.473 Billion USD, Growing 25.5% at Constant Currency - 23.04.2026, 07:00:03 Uhr
- BUSINESS WIRE: Galderma Shareholders Approve All Annual General Meeting Proposals - 22.04.2026, 17:45:02 Uhr
